Drug Insights

Is Lonafarnib approved by the FDA?

9 July 2024
3 min read

Yes, Lonafarnib (Zokinvy) is an FDA-approved medication for treating Hutchinson-Gilford Progeria Syndrome and certain processing-deficient Progeroid Laminopathies. Approved on November 20, 2020, it offers a vital treatment option for managing these rare genetic conditions.

What is Lonafarnib?

Lonafarnib, marketed under the brand name Zokinvy, is an oral medication used to treat specific rare genetic conditions that cause premature and rapid aging. It is indicated for use in adults and children at least 12 months old with a body surface area of at least 0.39 square meters.

How Lonafarnib Works

Lonafarnib works by inhibiting a specific enzyme involved in the abnormal aging process seen in HGPS and certain Progeroid Laminopathies. By blocking this enzyme, Lonafarnib helps to reduce the harmful effects associated with these genetic conditions.

Indications

  • Hutchinson-Gilford Progeria Syndrome (HGPS): Lonafarnib is used to lower the risk of death in patients with HGPS.
  • Processing-Deficient Progeroid Laminopathies: It is also used to treat certain types of Progeroid Laminopathies that are processing-deficient.

Lonafarnib is not indicated for use in patients with non-HGPS Progeroid Syndromes or processing-proficient Progeroid Laminopathies.

Administration and Dosage

  • Dosage Form: Oral capsules (50 mg; 75 mg)
  • Administration: Typically taken with morning and evening meals. It should be swallowed with a full glass of water. If unable to swallow the capsule whole, the contents can be mixed with Ora Blend SF, Ora-Plus, orange juice, or applesauce and consumed immediately.

Potential Side Effects

Common Side Effects:

  • Electrolyte imbalances (low levels of potassium, sodium, or calcium)
  • Infection
  • Increased blood pressure
  • Stomach pain, nausea, vomiting, diarrhea
  • Decreased appetite, weight loss
  • Headache
  • Fatigue
  • Muscle or joint pain
  • Cold symptoms (stuffy nose, sneezing, sore throat, cough)
  • Abnormal lab tests

Serious Side Effects:

  • New or worsening vision problems
  • Severe ongoing nausea, vomiting, diarrhea
  • Loss of appetite causing weight loss
  • High blood pressure
  • Kidney problems
  • High potassium level
  • Low potassium level
  • Low sodium level
  • Low calcium level
  • Signs of infection

Patients should seek emergency medical help if they experience signs of an allergic reaction such as hives, difficulty breathing, or swelling of the face, lips, tongue, or throat.

Warnings and Precautions

  • Drug Interactions: Many drugs can interact with Lonafarnib, and some should not be used together. Inform your doctor about all your current medications.
  • Pregnancy and Fertility: Lonafarnib may harm an unborn baby and affect fertility. Effective birth control should be used to prevent pregnancy.
  • Breastfeeding: It may not be safe to breastfeed while using this medication. Consult your doctor about any risks.

How to obtain the latest development progress of all drugs?

In the Synapse database, you can stay updated on the latest research and development advances of all drugs. This service is accessible anytime and anywhere, with updates available daily or weekly. Use the "Set Alert" function to stay informed. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Eirion Therapeutics Begins First Human Trials for Topical ET-02 in Androgenic Alopecia Treatment
Latest Hotspot
3 min read
Eirion Therapeutics Begins First Human Trials for Topical ET-02 in Androgenic Alopecia Treatment
9 July 2024
Eirion Therapeutics Inc. has reported the enrollment of the initial participant in a Phase 1 clinical study aimed at assessing the safety of their proprietary topical medication, ET-02, for the treatment of androgenic alopecia.
Read →
Is Inmazeb approved by the FDA?
Drug Insights
2 min read
Is Inmazeb approved by the FDA?
9 July 2024
Approved on October 14, 2020, it provides a crucial option for managing and treating Ebola virus disease.
Read →
Global New Drug Research and Development Progress Weekly Report(7.1-7.7)
Drug Highlight
10 min read
Global New Drug Research and Development Progress Weekly Report(7.1-7.7)
8 July 2024
7.1-7.7 Global Drug R&D Progress & Pharmaceutical Transaction Trends.
Read →
Is Pralsetinib approved by the FDA?
Drug Insights
3 min read
Is Pralsetinib approved by the FDA?
5 July 2024
Approved on September 4, 2020, pralsetinib (Gavreto) represents a significant advancement in targeted cancer therapy.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.